Denmark, July 28, 2014.
The 5´th International suPAR Symposium was successfully held in Amsterdam, The Netherlands on May 8-9, 2014.
The 1½ days at the historical venue Trippenhuis in central Amsterdam revealed high quality presentations with interesting and productive discussions during the 4 main sessions:
Session 1. Is there a Role for Biomarkers?
Session 2. Possible Ways to Use suPAR
Session 3. Latest Knowledge gained with suPAR Research
Session 4. Success Criteria´s for implementing a new Biomarker
You can see an overview of the meeting in a video film as well as the suPAR Symposium programme and several of the abstracts presented under
Events > 5´th International suPAR Symposium
On our YouTube channel https://www.youtube.com/user/suPARnostic you can see a handful of selected presentations from the meeting.
Denmark, June 25, 2014.
In June 2014, The European Science Open Festival, also called ESOF, was held in Copenhagen, Denmark.
Jesper Eugen-Olsen held a presentation on "suPAR, the Acute Care Triage marker" and Jakob Knudsen demonstrated the suPARnostic® Quick Triage system, used for quick determination of the plasma suPAR level.
The presentation was about suPAR, prognosis and risk of mortality, disease severity monitoring, and how the suPAR biomarker is being used in the Acute Care medical ward to optimize patient admission.
A 4-minute summary of the suPAR presentation and demonstration at ESOF can be seen if you go to the suPARnostic You Tube channel:
Denmark, May 2, 2014.
The cooperation between ViroGates and Copenhagen University Hospital Hvidovre, Denmark, is based on research started at Hvidovre Hospital in 1999. The amount of the protein suPAR in the blood was found to be a general marker for risk stratification of patients, indicating disease severity and monitoring patient survival.
This research has resulted in more than 250 published articles and the development of the suPARnostic® test.
Today, the suPARnostic® test is used on all patients at Hvidovre University Hospital in the acute care medical department, as part of the process of assessing disease severity and triaging of patients upon admission to the hospital.
Read the story behind this cooperation in the Danish articles in the Region H publications:
"Grundforskning førte til en ny test til at måle graden af sygdom": Region H.pdf
Also read the Danish article in the magazine Sygeplejersken 8, June 27, 2014, about the cooperation between Brøndby Kommune and Hvidovre Hospital, in their effort to bring the number of readmissions to the hospital down, using the suPARnostic® test.
Denmark, March 27, 2014
New Austrian study shows that the biomarker suPAR is able to predict mortality for patients at a very early stage of blood poisoning [sepsis/SIRS]. These findings demonstrate again that suPARnostic® is superior to other wellknown biomarker products used today upon admission to the Emergency Department.
Early triage of patients presents a major challenge
Infectious and inflammatory conditions such as SIRS (Systemic inflammatory response syndrome) or sepsis is observed frequently in hospitals and can progress rapidly to life-threatening conditions. Current biomarkers (such as CRP, PCT and IL-6) are widely used in SIRS and sepsis, but a biomarker that convincingly predicts mortality at an early stage has been lacking.
Prognostic potential of suPARnostic® investigated
Reinhard B. Raggam, Jasmin Wagner et. al. (http://www.ncbi.nlm.nih.gov/pubmed/24645798) have conducted a study at the Medical University of Graz, Austria investigating how different biomarkers are able to predict mortality for patients at an early SIRS stage.
The prognostic potential of suPARnostic® was compared with that of routinely tested biomarkers (CRP, PCT and IL-6) for 48-hours, 30-days and 90-days mortality in 902 patients presenting with SIRS.
suPAR measured by suPARnostic® superior to other biomarkers
Results show that suPARnostic® is superior to other biomarker based products (IL-6, PCT, CRP) and serves as an ideal prognostic marker in SIRS patients being an independent predictor of 48-hours, 30-day and 90-day mortality.
The study concludes that suPAR levels can be used for triage in the Emergency Department, to determine which patients require more comprehensive monitoring, and that suPARnostic® is superior to other products - especially when it comes to predicting mortality.
“The new data from Austria confirm findings from earlier studies in both Denmark and Finland that have led to clinical routine use of the marker in the Emergency Department. It highlights yet again how suPARnostic® plays a major role in acute medical decision making” says Jakob Knudsen, CEO, ViroGates A/S.
“suPARnostic® reliably discriminates between survivors and non-survivors, and allows a much better risk stratification compared to the classical markers. Adding suPARnostic® will help the clinician in the Emergency Department in making correct triage decisions, and to prioritize those patients with urgent need for hospitalization”.
Denmark, March 17, 2014
ViroGates has signed up with a new distributor in Norway:
Electra-Box Diagnostica AS
Tel: +47 415 58 011
Contact: Andrey Sokolov
ViroGates already has a distribution agreement with Electra-Box Diagnostica in Sweden and Finland, and will now expand this cooperation to include Norway as well.